| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiomyopathy, Hypertrophic | 263 | 2025 | 753 | 50.260 |
Why?
|
| Death, Sudden, Cardiac | 78 | 2024 | 349 | 13.750 |
Why?
|
| Defibrillators, Implantable | 45 | 2024 | 259 | 10.780 |
Why?
|
| Ventricular Outflow Obstruction | 41 | 2025 | 113 | 9.040 |
Why?
|
| Heart Failure | 41 | 2024 | 858 | 7.880 |
Why?
|
| Magnetic Resonance Imaging, Cine | 34 | 2024 | 107 | 6.270 |
Why?
|
| Magnetic Resonance Imaging | 45 | 2023 | 2064 | 4.400 |
Why?
|
| Atrial Fibrillation | 24 | 2024 | 809 | 4.400 |
Why?
|
| Athletes | 17 | 2024 | 101 | 4.400 |
Why?
|
| Cardiology | 16 | 2021 | 163 | 4.270 |
Why?
|
| Humans | 311 | 2025 | 59736 | 4.240 |
Why?
|
| Hypertrophy, Left Ventricular | 19 | 2023 | 122 | 4.200 |
Why?
|
| Myocardium | 22 | 2024 | 265 | 4.190 |
Why?
|
| Ventricular Septum | 10 | 2022 | 30 | 4.130 |
Why?
|
| Cardiac Surgical Procedures | 17 | 2022 | 252 | 3.990 |
Why?
|
| Heart Ventricles | 28 | 2022 | 255 | 3.740 |
Why?
|
| Heart Transplantation | 12 | 2024 | 164 | 3.260 |
Why?
|
| Tachycardia, Ventricular | 14 | 2023 | 121 | 3.210 |
Why?
|
| Echocardiography | 34 | 2024 | 465 | 3.140 |
Why?
|
| Risk Assessment | 38 | 2024 | 1935 | 3.110 |
Why?
|
| Benzylamines | 10 | 2025 | 30 | 3.060 |
Why?
|
| Heart Aneurysm | 7 | 2021 | 23 | 2.900 |
Why?
|
| Cardiomyopathies | 9 | 2022 | 119 | 2.890 |
Why?
|
| Male | 162 | 2025 | 27948 | 2.790 |
Why?
|
| Gadolinium | 15 | 2024 | 103 | 2.760 |
Why?
|
| Middle Aged | 120 | 2025 | 16452 | 2.760 |
Why?
|
| Adult | 121 | 2025 | 15771 | 2.710 |
Why?
|
| Disease Management | 9 | 2024 | 220 | 2.620 |
Why?
|
| Cardiomyopathy, Hypertrophic, Familial | 11 | 2023 | 28 | 2.550 |
Why?
|
| Uracil | 10 | 2025 | 30 | 2.510 |
Why?
|
| Prognosis | 39 | 2024 | 1613 | 2.410 |
Why?
|
| Contrast Media | 19 | 2022 | 408 | 2.400 |
Why?
|
| Phenotype | 29 | 2024 | 1142 | 2.330 |
Why?
|
| Sports | 8 | 2024 | 94 | 2.290 |
Why?
|
| Female | 148 | 2025 | 30921 | 2.220 |
Why?
|
| Risk Factors | 52 | 2024 | 5011 | 2.220 |
Why?
|
| Electric Countershock | 13 | 2024 | 100 | 2.210 |
Why?
|
| Treatment Outcome | 50 | 2025 | 5333 | 2.180 |
Why?
|
| Electrocardiography | 29 | 2024 | 524 | 2.110 |
Why?
|
| Exercise Test | 9 | 2024 | 242 | 2.020 |
Why?
|
| Aged | 75 | 2025 | 13512 | 1.920 |
Why?
|
| American Heart Association | 13 | 2020 | 122 | 1.910 |
Why?
|
| Young Adult | 42 | 2025 | 4290 | 1.820 |
Why?
|
| Ventricular Dysfunction, Left | 10 | 2020 | 158 | 1.800 |
Why?
|
| Exercise Tolerance | 6 | 2024 | 75 | 1.770 |
Why?
|
| Ventricular Function, Left | 22 | 2025 | 258 | 1.740 |
Why?
|
| Heart Septum | 15 | 2022 | 55 | 1.680 |
Why?
|
| Primary Prevention | 9 | 2021 | 134 | 1.600 |
Why?
|
| Follow-Up Studies | 37 | 2025 | 2354 | 1.570 |
Why?
|
| Cardiovascular Agents | 4 | 2024 | 99 | 1.510 |
Why?
|
| Genetic Predisposition to Disease | 14 | 2024 | 679 | 1.510 |
Why?
|
| Papillary Muscles | 7 | 2015 | 13 | 1.470 |
Why?
|
| Genetic Testing | 9 | 2024 | 127 | 1.460 |
Why?
|
| Mitral Valve | 6 | 2020 | 108 | 1.430 |
Why?
|
| Adolescent | 38 | 2025 | 5865 | 1.430 |
Why?
|
| Predictive Value of Tests | 24 | 2022 | 1038 | 1.360 |
Why?
|
| Catheter Ablation | 7 | 2023 | 149 | 1.320 |
Why?
|
| Advisory Committees | 6 | 2015 | 108 | 1.310 |
Why?
|
| Cardiovascular Diseases | 7 | 2023 | 791 | 1.230 |
Why?
|
| Stroke Volume | 19 | 2025 | 315 | 1.200 |
Why?
|
| Genotype | 8 | 2024 | 621 | 1.190 |
Why?
|
| Mutation | 16 | 2024 | 2462 | 1.190 |
Why?
|
| Vascular Diseases | 3 | 2024 | 75 | 1.180 |
Why?
|
| Mass Screening | 6 | 2019 | 654 | 1.170 |
Why?
|
| Child | 26 | 2024 | 4212 | 1.160 |
Why?
|
| Practice Guidelines as Topic | 8 | 2024 | 707 | 1.140 |
Why?
|
| United States | 39 | 2025 | 7448 | 1.130 |
Why?
|
| Double-Blind Method | 11 | 2024 | 715 | 1.130 |
Why?
|
| Fibrosis | 15 | 2023 | 154 | 1.100 |
Why?
|
| Echocardiography, Doppler | 11 | 2017 | 133 | 1.090 |
Why?
|
| Patient Selection | 11 | 2024 | 467 | 1.080 |
Why?
|
| Ventricular Fibrillation | 10 | 2023 | 98 | 1.060 |
Why?
|
| Survival Rate | 14 | 2024 | 804 | 1.040 |
Why?
|
| Amyloidosis | 3 | 2022 | 62 | 1.010 |
Why?
|
| Aged, 80 and over | 29 | 2025 | 5150 | 1.000 |
Why?
|
| Cardiovascular Abnormalities | 6 | 2015 | 32 | 1.000 |
Why?
|
| Cicatrix | 7 | 2024 | 59 | 0.990 |
Why?
|
| Heart Arrest | 4 | 2022 | 161 | 0.990 |
Why?
|
| Amyloid Neuropathies, Familial | 2 | 2022 | 16 | 0.990 |
Why?
|
| Takotsubo Cardiomyopathy | 9 | 2021 | 64 | 0.980 |
Why?
|
| Retrospective Studies | 37 | 2025 | 6152 | 0.970 |
Why?
|
| Echocardiography, Three-Dimensional | 6 | 2016 | 41 | 0.960 |
Why?
|
| Heart | 9 | 2024 | 275 | 0.940 |
Why?
|
| Endpoint Determination | 1 | 2024 | 24 | 0.930 |
Why?
|
| Cohort Studies | 20 | 2024 | 2387 | 0.920 |
Why?
|
| Image Enhancement | 6 | 2021 | 189 | 0.910 |
Why?
|
| Cardiac Imaging Techniques | 5 | 2022 | 17 | 0.900 |
Why?
|
| Fabry Disease | 2 | 2017 | 8 | 0.900 |
Why?
|
| Arrhythmias, Cardiac | 6 | 2024 | 146 | 0.870 |
Why?
|
| Time Factors | 20 | 2025 | 3629 | 0.860 |
Why?
|
| Prevalence | 18 | 2023 | 1262 | 0.850 |
Why?
|
| Hemodynamics | 4 | 2017 | 231 | 0.850 |
Why?
|
| Disease Progression | 12 | 2024 | 1126 | 0.830 |
Why?
|
| Anti-Arrhythmia Agents | 10 | 2025 | 97 | 0.830 |
Why?
|
| Sarcomeres | 8 | 2024 | 51 | 0.830 |
Why?
|
| Prospective Studies | 23 | 2024 | 3090 | 0.830 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 679 | 0.790 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2020 | 15 | 0.790 |
Why?
|
| Cardiovascular System | 1 | 2022 | 38 | 0.770 |
Why?
|
| Heart Diseases | 4 | 2019 | 207 | 0.760 |
Why?
|
| Biomarkers | 10 | 2024 | 1315 | 0.760 |
Why?
|
| Physicians | 2 | 2020 | 445 | 0.760 |
Why?
|
| Gadolinium DTPA | 6 | 2017 | 85 | 0.730 |
Why?
|
| Systole | 6 | 2021 | 109 | 0.720 |
Why?
|
| Quality of Life | 10 | 2024 | 1142 | 0.710 |
Why?
|
| Ethanol | 3 | 2023 | 309 | 0.690 |
Why?
|
| Diagnostic Imaging | 2 | 2016 | 246 | 0.690 |
Why?
|
| Glycogen Storage Disease | 1 | 2020 | 3 | 0.690 |
Why?
|
| Judgment | 1 | 2020 | 34 | 0.680 |
Why?
|
| Echocardiography, Stress | 3 | 2017 | 13 | 0.670 |
Why?
|
| Consensus | 4 | 2020 | 193 | 0.660 |
Why?
|
| Europe | 9 | 2024 | 182 | 0.660 |
Why?
|
| Incidence | 8 | 2022 | 1243 | 0.650 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2016 | 35 | 0.630 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 2 | 2015 | 13 | 0.620 |
Why?
|
| Registries | 10 | 2024 | 805 | 0.610 |
Why?
|
| Heart Failure, Systolic | 2 | 2021 | 16 | 0.610 |
Why?
|
| Oxygen Consumption | 4 | 2024 | 207 | 0.610 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2017 | 98 | 0.610 |
Why?
|
| Spironolactone | 1 | 2018 | 9 | 0.590 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2018 | 12 | 0.590 |
Why?
|
| Congresses as Topic | 1 | 2018 | 72 | 0.580 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 98 | 0.580 |
Why?
|
| Myocarditis | 2 | 2015 | 61 | 0.580 |
Why?
|
| Tertiary Healthcare | 1 | 2017 | 13 | 0.570 |
Why?
|
| Kidney Diseases | 1 | 2019 | 172 | 0.570 |
Why?
|
| Diagnosis, Differential | 12 | 2019 | 943 | 0.560 |
Why?
|
| Ventricular Remodeling | 8 | 2024 | 80 | 0.560 |
Why?
|
| Carrier Proteins | 7 | 2024 | 697 | 0.560 |
Why?
|
| Image Interpretation, Computer-Assisted | 7 | 2024 | 170 | 0.550 |
Why?
|
| Global Health | 5 | 2021 | 168 | 0.550 |
Why?
|
| Cause of Death | 5 | 2025 | 210 | 0.540 |
Why?
|
| Cost of Illness | 1 | 2018 | 156 | 0.540 |
Why?
|
| Stroke | 5 | 2024 | 1134 | 0.540 |
Why?
|
| Severity of Illness Index | 15 | 2019 | 1489 | 0.520 |
Why?
|
| Proportional Hazards Models | 10 | 2021 | 674 | 0.520 |
Why?
|
| Sodium Channel Blockers | 1 | 2016 | 10 | 0.510 |
Why?
|
| Ablation Techniques | 4 | 2020 | 22 | 0.510 |
Why?
|
| Cardiac Myosins | 4 | 2024 | 22 | 0.510 |
Why?
|
| Societies, Medical | 2 | 2015 | 339 | 0.490 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2015 | 22 | 0.480 |
Why?
|
| Embolization, Therapeutic | 2 | 2015 | 310 | 0.470 |
Why?
|
| Case-Control Studies | 9 | 2021 | 1061 | 0.460 |
Why?
|
| Glycogen Storage Disease Type IIb | 1 | 2014 | 4 | 0.450 |
Why?
|
| Reproducibility of Results | 9 | 2022 | 1570 | 0.450 |
Why?
|
| Pedigree | 6 | 2019 | 183 | 0.440 |
Why?
|
| Heart Atria | 5 | 2021 | 137 | 0.440 |
Why?
|
| Sequoia | 2 | 2023 | 2 | 0.430 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2022 | 291 | 0.430 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 121 | 0.430 |
Why?
|
| Heart Failure, Diastolic | 1 | 2013 | 9 | 0.430 |
Why?
|
| Ventricular Dysfunction | 2 | 2010 | 11 | 0.430 |
Why?
|
| Endomyocardial Fibrosis | 2 | 2015 | 4 | 0.420 |
Why?
|
| Decision Making | 1 | 2017 | 395 | 0.410 |
Why?
|
| Specialties, Surgical | 1 | 2013 | 45 | 0.410 |
Why?
|
| Penetrance | 1 | 2013 | 10 | 0.410 |
Why?
|
| Electrodes | 1 | 2013 | 35 | 0.410 |
Why?
|
| Cardiotonic Agents | 3 | 2018 | 50 | 0.410 |
Why?
|
| Scalp | 1 | 2013 | 29 | 0.410 |
Why?
|
| Disopyramide | 4 | 2025 | 11 | 0.390 |
Why?
|
| Age Factors | 9 | 2019 | 1511 | 0.380 |
Why?
|
| Recovery of Function | 6 | 2020 | 271 | 0.380 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 150 | 0.380 |
Why?
|
| Peptide Fragments | 3 | 2024 | 401 | 0.380 |
Why?
|
| Obesity | 2 | 2025 | 1170 | 0.370 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 450 | 0.360 |
Why?
|
| Mortality | 3 | 2025 | 156 | 0.360 |
Why?
|
| Clinical Decision-Making | 4 | 2019 | 150 | 0.360 |
Why?
|
| Precision Medicine | 2 | 2022 | 102 | 0.350 |
Why?
|
| Patient Care Management | 2 | 2020 | 30 | 0.350 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1192 | 0.350 |
Why?
|
| Myosin Heavy Chains | 3 | 2017 | 42 | 0.340 |
Why?
|
| Health Status | 3 | 2024 | 426 | 0.330 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2022 | 85 | 0.330 |
Why?
|
| Conservation of Natural Resources | 2 | 2022 | 14 | 0.320 |
Why?
|
| Hypertension, Pulmonary | 2 | 2022 | 92 | 0.310 |
Why?
|
| Terminology as Topic | 4 | 2018 | 133 | 0.310 |
Why?
|
| Coronary Aneurysm | 1 | 2008 | 7 | 0.310 |
Why?
|
| Myocardial Ischemia | 1 | 2009 | 112 | 0.310 |
Why?
|
| Infant, Newborn | 1 | 2013 | 1288 | 0.300 |
Why?
|
| Tachycardia | 1 | 2008 | 28 | 0.290 |
Why?
|
| Valsalva Maneuver | 2 | 2024 | 11 | 0.290 |
Why?
|
| Adrenergic beta-Antagonists | 6 | 2024 | 147 | 0.290 |
Why?
|
| Adipose Tissue | 1 | 2010 | 286 | 0.290 |
Why?
|
| DNA Mutational Analysis | 5 | 2014 | 192 | 0.290 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 330 | 0.280 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2024 | 53 | 0.280 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2007 | 7 | 0.280 |
Why?
|
| Sex Factors | 6 | 2019 | 940 | 0.270 |
Why?
|
| Multivariate Analysis | 5 | 2015 | 909 | 0.260 |
Why?
|
| Longevity | 2 | 2017 | 110 | 0.260 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 2 | 2017 | 14 | 0.260 |
Why?
|
| Anticoagulants | 5 | 2024 | 480 | 0.250 |
Why?
|
| Myocardial Contraction | 2 | 2024 | 85 | 0.250 |
Why?
|
| Troponin I | 2 | 2024 | 34 | 0.250 |
Why?
|
| Ventricular Function | 3 | 2017 | 22 | 0.240 |
Why?
|
| Ultrasonography | 6 | 2011 | 458 | 0.240 |
Why?
|
| Electrocardiography, Ambulatory | 3 | 2017 | 40 | 0.240 |
Why?
|
| Australia | 5 | 2018 | 86 | 0.240 |
Why?
|
| Referral and Consultation | 2 | 2019 | 405 | 0.240 |
Why?
|
| Genetic Therapy | 2 | 2024 | 735 | 0.240 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2025 | 24 | 0.230 |
Why?
|
| Biodiversity | 2 | 2022 | 19 | 0.230 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 91 | 0.220 |
Why?
|
| Aortic Valve | 2 | 2017 | 175 | 0.220 |
Why?
|
| Boston | 3 | 2020 | 248 | 0.220 |
Why?
|
| Atrial Appendage | 1 | 2024 | 30 | 0.210 |
Why?
|
| Universities | 1 | 2024 | 144 | 0.210 |
Why?
|
| Administration, Oral | 1 | 2024 | 354 | 0.210 |
Why?
|
| Prealbumin | 1 | 2022 | 19 | 0.200 |
Why?
|
| Soccer | 1 | 2022 | 13 | 0.200 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2013 | 22 | 0.200 |
Why?
|
| Proteomics | 1 | 2024 | 266 | 0.200 |
Why?
|
| Morbidity | 2 | 2020 | 113 | 0.200 |
Why?
|
| Forecasting | 2 | 2014 | 223 | 0.200 |
Why?
|
| Heart Defects, Congenital | 2 | 2018 | 94 | 0.200 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2021 | 77 | 0.190 |
Why?
|
| Blood Pressure | 2 | 2017 | 498 | 0.190 |
Why?
|
| Equipment Failure | 2 | 2019 | 65 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2015 | 1540 | 0.190 |
Why?
|
| Demography | 1 | 2022 | 170 | 0.190 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2021 | 18 | 0.190 |
Why?
|
| Genetic Counseling | 2 | 2019 | 15 | 0.180 |
Why?
|
| Coronary Artery Bypass | 2 | 2022 | 280 | 0.180 |
Why?
|
| New Jersey | 2 | 2018 | 26 | 0.180 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 440 | 0.180 |
Why?
|
| Gene Expression Profiling | 1 | 2024 | 727 | 0.180 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 127 | 0.180 |
Why?
|
| Publication Bias | 1 | 2020 | 20 | 0.180 |
Why?
|
| Subcutaneous Tissue | 1 | 2020 | 14 | 0.170 |
Why?
|
| Chi-Square Distribution | 5 | 2013 | 409 | 0.170 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2019 | 278 | 0.170 |
Why?
|
| Evidence-Based Medicine | 5 | 2020 | 444 | 0.170 |
Why?
|
| Animals | 8 | 2024 | 19702 | 0.170 |
Why?
|
| Syncope | 3 | 2022 | 41 | 0.170 |
Why?
|
| Autopsy | 1 | 2020 | 54 | 0.170 |
Why?
|
| Pandemics | 1 | 2025 | 618 | 0.170 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 9 | 0.170 |
Why?
|
| Survival Analysis | 7 | 2019 | 558 | 0.170 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2020 | 68 | 0.170 |
Why?
|
| Proteome | 1 | 2021 | 141 | 0.170 |
Why?
|
| Diseases in Twins | 1 | 2020 | 55 | 0.160 |
Why?
|
| History, 21st Century | 3 | 2016 | 162 | 0.160 |
Why?
|
| Ecosystem | 2 | 2022 | 38 | 0.160 |
Why?
|
| Vertebrates | 2 | 2022 | 41 | 0.160 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 149 | 0.160 |
Why?
|
| History, 20th Century | 3 | 2016 | 224 | 0.160 |
Why?
|
| Channelopathies | 1 | 2019 | 5 | 0.160 |
Why?
|
| Radionuclide Imaging | 2 | 2009 | 121 | 0.160 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 21 | 0.160 |
Why?
|
| Shock, Cardiogenic | 2 | 2021 | 87 | 0.160 |
Why?
|
| Massachusetts | 3 | 2020 | 2027 | 0.160 |
Why?
|
| Neuromuscular Diseases | 1 | 2019 | 20 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2013 | 402 | 0.160 |
Why?
|
| Child, Preschool | 3 | 2017 | 1799 | 0.160 |
Why?
|
| Models, Animal | 1 | 2019 | 224 | 0.160 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 101 | 0.150 |
Why?
|
| Models, Theoretical | 1 | 2020 | 257 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2019 | 153 | 0.150 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2017 | 26 | 0.150 |
Why?
|
| Guideline Adherence | 2 | 2019 | 296 | 0.150 |
Why?
|
| Procollagen | 1 | 2018 | 10 | 0.150 |
Why?
|
| Medicare | 1 | 2022 | 601 | 0.150 |
Why?
|
| Collagen Type I | 1 | 2018 | 39 | 0.150 |
Why?
|
| Asymptomatic Diseases | 2 | 2017 | 47 | 0.150 |
Why?
|
| Waiting Lists | 1 | 2018 | 48 | 0.140 |
Why?
|
| alpha-Galactosidase | 1 | 2017 | 7 | 0.140 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2017 | 9 | 0.140 |
Why?
|
| Minnesota | 3 | 2015 | 40 | 0.140 |
Why?
|
| Dyspnea | 1 | 2018 | 116 | 0.140 |
Why?
|
| Critical Pathways | 1 | 2017 | 32 | 0.140 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 3 | 2022 | 19 | 0.140 |
Why?
|
| Comorbidity | 3 | 2021 | 1083 | 0.140 |
Why?
|
| Analysis of Variance | 3 | 2014 | 592 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 203 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2018 | 137 | 0.130 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 88 | 0.130 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 250 | 0.130 |
Why?
|
| Israel | 1 | 2016 | 19 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2019 | 719 | 0.130 |
Why?
|
| Postoperative Complications | 2 | 2023 | 1217 | 0.130 |
Why?
|
| Rats | 1 | 2019 | 1911 | 0.130 |
Why?
|
| Thoracic Surgery | 1 | 2017 | 68 | 0.130 |
Why?
|
| Insurance Claim Review | 1 | 2016 | 76 | 0.130 |
Why?
|
| Heart-Assist Devices | 1 | 2018 | 131 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2016 | 137 | 0.120 |
Why?
|
| Intraoperative Complications | 1 | 2015 | 88 | 0.120 |
Why?
|
| Myocardial Infarction | 3 | 2012 | 864 | 0.120 |
Why?
|
| Invertebrates | 1 | 2014 | 21 | 0.120 |
Why?
|
| Plants | 1 | 2014 | 45 | 0.120 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2014 | 7 | 0.120 |
Why?
|
| Heredity | 1 | 2014 | 6 | 0.110 |
Why?
|
| Inflammation | 1 | 2021 | 1101 | 0.110 |
Why?
|
| Single-Blind Method | 1 | 2014 | 137 | 0.110 |
Why?
|
| Atrial Remodeling | 1 | 2014 | 17 | 0.110 |
Why?
|
| Ventricular Function, Right | 1 | 2014 | 27 | 0.110 |
Why?
|
| Atrial Function, Left | 1 | 2014 | 31 | 0.110 |
Why?
|
| Decision Support Techniques | 3 | 2020 | 180 | 0.110 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2014 | 42 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 311 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 399 | 0.110 |
Why?
|
| Italy | 1 | 2013 | 63 | 0.100 |
Why?
|
| Likelihood Functions | 1 | 2013 | 68 | 0.100 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 179 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2012 | 442 | 0.100 |
Why?
|
| Heart Valve Diseases | 1 | 2014 | 90 | 0.100 |
Why?
|
| Research Design | 1 | 2016 | 556 | 0.100 |
Why?
|
| False Negative Reactions | 1 | 2012 | 40 | 0.100 |
Why?
|
| Calcium Channel Blockers | 2 | 2024 | 58 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2024 | 810 | 0.100 |
Why?
|
| Cardiac Catheterization | 3 | 2024 | 254 | 0.100 |
Why?
|
| Microfilament Proteins | 1 | 2012 | 108 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2013 | 653 | 0.090 |
Why?
|
| Aortic Valve Stenosis | 1 | 2014 | 172 | 0.090 |
Why?
|
| Hypothermia, Induced | 1 | 2011 | 40 | 0.090 |
Why?
|
| Troponin T | 2 | 2008 | 23 | 0.090 |
Why?
|
| Mice | 2 | 2024 | 10316 | 0.090 |
Why?
|
| Canada | 3 | 2017 | 147 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2016 | 850 | 0.090 |
Why?
|
| Risk Adjustment | 2 | 2020 | 93 | 0.080 |
Why?
|
| Logistic Models | 2 | 2010 | 1240 | 0.080 |
Why?
|
| Brachial Artery | 1 | 2010 | 28 | 0.080 |
Why?
|
| Transcriptome | 2 | 2024 | 345 | 0.080 |
Why?
|
| Vasodilation | 1 | 2010 | 35 | 0.080 |
Why?
|
| Coronary Angiography | 3 | 2019 | 178 | 0.080 |
Why?
|
| DNA | 1 | 2014 | 806 | 0.080 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 95 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2013 | 837 | 0.080 |
Why?
|
| Statistics, Nonparametric | 3 | 2017 | 210 | 0.080 |
Why?
|
| Biopsy | 1 | 2010 | 420 | 0.080 |
Why?
|
| Research | 1 | 2010 | 187 | 0.080 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2008 | 7 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 200 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 170 | 0.080 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2008 | 20 | 0.080 |
Why?
|
| Muscles | 1 | 2009 | 173 | 0.080 |
Why?
|
| Circadian Rhythm | 1 | 2012 | 373 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2013 | 688 | 0.080 |
Why?
|
| Tertiary Care Centers | 2 | 2020 | 101 | 0.080 |
Why?
|
| Ventricular Premature Complexes | 1 | 2008 | 21 | 0.070 |
Why?
|
| Genomics | 2 | 2022 | 322 | 0.070 |
Why?
|
| Confidence Intervals | 3 | 2013 | 242 | 0.070 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 186 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2008 | 93 | 0.070 |
Why?
|
| Hypertension | 1 | 2013 | 570 | 0.070 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2008 | 36 | 0.070 |
Why?
|
| Diastole | 3 | 2016 | 89 | 0.070 |
Why?
|
| Sports Medicine | 1 | 2007 | 23 | 0.070 |
Why?
|
| Cardiac Output, Low | 1 | 2006 | 10 | 0.070 |
Why?
|
| Thrombolytic Therapy | 1 | 2008 | 184 | 0.070 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 2 | 2017 | 24 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 637 | 0.060 |
Why?
|
| Databases, Factual | 3 | 2017 | 818 | 0.060 |
Why?
|
| Troponin | 2 | 2019 | 36 | 0.060 |
Why?
|
| Algorithms | 2 | 2020 | 981 | 0.060 |
Why?
|
| Infant | 2 | 2011 | 1495 | 0.060 |
Why?
|
| Stress, Physiological | 1 | 2007 | 185 | 0.060 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2024 | 4 | 0.060 |
Why?
|
| Stress, Psychological | 2 | 2010 | 445 | 0.060 |
Why?
|
| Exercise | 1 | 2012 | 884 | 0.060 |
Why?
|
| Cats | 1 | 2024 | 83 | 0.060 |
Why?
|
| Standard of Care | 1 | 2024 | 27 | 0.060 |
Why?
|
| Withholding Treatment | 1 | 2024 | 40 | 0.060 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 113 | 0.060 |
Why?
|
| Myocytes, Cardiac | 1 | 2024 | 88 | 0.060 |
Why?
|
| Septal Occluder Device | 1 | 2024 | 11 | 0.060 |
Why?
|
| Bundle-Branch Block | 1 | 2024 | 14 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2024 | 65 | 0.060 |
Why?
|
| Species Specificity | 1 | 2024 | 329 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2005 | 488 | 0.060 |
Why?
|
| Iatrogenic Disease | 1 | 2024 | 61 | 0.050 |
Why?
|
| Propensity Score | 1 | 2024 | 146 | 0.050 |
Why?
|
| Death, Sudden | 1 | 2023 | 28 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2023 | 134 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2019 | 850 | 0.050 |
Why?
|
| Physical Exertion | 2 | 2017 | 79 | 0.050 |
Why?
|
| Insecta | 1 | 2022 | 37 | 0.050 |
Why?
|
| Vascular Remodeling | 1 | 2022 | 24 | 0.050 |
Why?
|
| Darkness | 1 | 2021 | 22 | 0.050 |
Why?
|
| Cell Communication | 1 | 2022 | 124 | 0.050 |
Why?
|
| Ontario | 1 | 2021 | 43 | 0.050 |
Why?
|
| Endophenotypes | 1 | 2021 | 8 | 0.050 |
Why?
|
| Heart Conduction System | 1 | 2021 | 50 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2022 | 133 | 0.040 |
Why?
|
| Multi-Institutional Systems | 1 | 2020 | 5 | 0.040 |
Why?
|
| Protein Interaction Maps | 1 | 2021 | 33 | 0.040 |
Why?
|
| Ligands | 1 | 2022 | 411 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 2388 | 0.040 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2020 | 7 | 0.040 |
Why?
|
| Ultrasonography, Doppler | 2 | 2010 | 25 | 0.040 |
Why?
|
| Twins, Monozygotic | 1 | 2020 | 69 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 170 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 155 | 0.040 |
Why?
|
| Rest | 2 | 2010 | 44 | 0.040 |
Why?
|
| Community Health Services | 1 | 2020 | 120 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 334 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 413 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 36 | 0.040 |
Why?
|
| Automation | 1 | 2018 | 51 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2018 | 71 | 0.040 |
Why?
|
| Sotalol | 1 | 2017 | 9 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 2060 | 0.040 |
Why?
|
| Amiodarone | 1 | 2017 | 20 | 0.040 |
Why?
|
| Hospitalization | 1 | 2025 | 1300 | 0.040 |
Why?
|
| Vascular Resistance | 1 | 2017 | 48 | 0.030 |
Why?
|
| Age Distribution | 2 | 2009 | 251 | 0.030 |
Why?
|
| Action Potentials | 1 | 2017 | 102 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2018 | 357 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 187 | 0.030 |
Why?
|
| Syndrome | 2 | 2007 | 173 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 608 | 0.030 |
Why?
|
| Heart Rate | 1 | 2017 | 309 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2015 | 69 | 0.030 |
Why?
|
| Probability | 2 | 2005 | 170 | 0.030 |
Why?
|
| Mental Health | 1 | 2018 | 336 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2016 | 212 | 0.030 |
Why?
|
| Endangered Species | 1 | 2014 | 2 | 0.030 |
Why?
|
| Anxiety | 1 | 2018 | 388 | 0.030 |
Why?
|
| Athletic Injuries | 1 | 2015 | 77 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2015 | 70 | 0.030 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2014 | 46 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 519 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 268 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2012 | 7 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2013 | 242 | 0.030 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2015 | 160 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 403 | 0.030 |
Why?
|
| Genetic Privacy | 1 | 2012 | 4 | 0.030 |
Why?
|
| Bisoprolol | 1 | 2012 | 2 | 0.020 |
Why?
|
| Nadolol | 1 | 2012 | 4 | 0.020 |
Why?
|
| Frameshift Mutation | 1 | 2012 | 29 | 0.020 |
Why?
|
| Introns | 1 | 2012 | 104 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 89 | 0.020 |
Why?
|
| Physical Endurance | 1 | 2012 | 45 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2012 | 172 | 0.020 |
Why?
|
| Radionuclide Ventriculography | 1 | 2011 | 5 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 117 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 452 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2021 | 2905 | 0.020 |
Why?
|
| Ventricular Pressure | 1 | 2010 | 30 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 1302 | 0.020 |
Why?
|
| Posture | 1 | 2010 | 127 | 0.020 |
Why?
|
| Goals | 1 | 2010 | 88 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 1955 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2011 | 205 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2008 | 118 | 0.020 |
Why?
|
| Atenolol | 1 | 2007 | 9 | 0.020 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2007 | 17 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2007 | 117 | 0.020 |
Why?
|
| Volunteers | 1 | 2007 | 16 | 0.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2007 | 167 | 0.020 |
Why?
|
| Time | 1 | 2005 | 26 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 244 | 0.010 |
Why?
|
| Decision Trees | 1 | 2004 | 51 | 0.010 |
Why?
|
| Chest Pain | 1 | 2005 | 81 | 0.010 |
Why?
|
| Heart Murmurs | 1 | 2003 | 3 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 1104 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 660 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 2520 | 0.010 |
Why?
|